BioNexus Gene Lab Corp. (BGLC) vs BHP Group Limited (BHP)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BGLC | BHP | |
|---|---|---|
| Sector | Basic Materials | Basic Materials |
| Industry | Specialty Chemicals | Other Industrial Metals & Mining |
| Size band | NANO | MEGA |
| Listing | Nasdaq CM | NYSE |
| Country | Malaysia | Australia |
| Theme | diagnostics | copper-mining |
| Price and returns | ||
| Last close | $1.16 | $79.13 |
| Return · 1 week | −5.54% | −4.91% |
| Return · 1 month | −10.77% | −6.44% |
| Return · 3 months | −14.07% | −5.56% |
| Return · year to date | −70.56% | +30.65% |
| Return · 1 year | −77.08% | +43.11% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −80.30% | −19.84% |
| 52-week high | $5.89 | $98.71 |
| 52-week low | $1.07 | $52.18 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $3.40M | $201.11B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $7.66K | $200.93M |
| Employees | 19 | 38,833 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 21.58× |
| Price to earnings · forward | — | 17.42× |
| Price to sales | 1.12× | 3.60× |
| Price to book | 0.37× | 4.15× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 7.59× |
| Enterprise value to revenue | 0.09× | 3.86× |
| PEG ratio | — | 5.95 |
| Earnings per share · trailing | -1.25 | 3.86 |
| Profitability | ||
| Gross margin | 12.34% | 75.58% |
| Operating margin | −398.69% | 43.34% |
| Profit margin | −82.36% | 16.73% |
| Return on equity | −33.66% | 24.00% |
| Return on assets | −18.99% | 13.43% |
| Growth | ||
| Revenue growth | −96.60% | +18.30% |
| Earnings growth | — | −9.00% |
| Balance sheet and payout | ||
| Debt / equity (%) | 4.16 | 50.47 |
| Current ratio | 6.08 | 1.89 |
| Dividend yield | 0.00% | 4.75% |
| Payout ratio | 0.00% | 68.84% |
| Trend and volatility | ||
| RSI · 14 | 37.38 | 33.14 |
| ADX · 14 | 7.82 | 19.41 |
| 50-day average | $1.39 | $87.57 |
| 200-day average | $2.02 | $81.11 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 5.89% | 2.55% |
The full BGLC analysis
Everything this table leaves out for BioNexus Gene Lab Corp.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BGLC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BGLC analysisThe full BHP analysis
Everything this table leaves out for BHP Group Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BHP argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BHP analysis